Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dr. Reddy's Laboratories has entered into a settlement agreement with Novartis Pharma, which involves a stipulation of dismissal of the lawsuits in the US relating to the abbreviated new drug applications filed by Dr. Reddy's, for the generic version of rivastigmine tartrate capsules sold under the trade-name Exelon.
Subscribe to our email newsletter
Under the terms of the agreement, Dr. Reddy’s will not launch its generic rivastigmine tartrate capsules until sometime before the expiry of the orange book patents claiming rivastigmine.
Rivastigmine tartrate capsules, the generic version of the Novartis product Exelon, are indicated for the treatment of mild-to-moderate Alzheimer’s disease, dementia.